96951 ⎘
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans; Cytokines; Lymphokines; Interferons Chemokines
Sub-classes:HETERODIMERIC HUMAN IgG1 POLYPEPTIDES WITH ISOELECTRIC POINT MODIFICATIONS
#2CHEMOKINE RESPONSIVE ACTIVATED NATURAL KILLER CELLS WITH SECONDARY HOMING ACTIVATION FOR VERIFIED TARGETS
#3Salmonella vectored therapies for treatment of cancer
#4CXC RECEPTOR LIGANDS
#5HETERODIMERIC HUMAN IgG1 POLYPEPTIDES WITH ISOELECTRIC POINT MODIFICATIONS
#6INTRACELLULAR CX3CL1 DOMAIN PEPTIDES AND USES THEREOF
#7ANTIMICROBIAL KINOCIDIN COMPOSITIONS AND METHODS OF USE
#8METHOD OF MANUFACTURING DIABETIC FOOT PATIENT-SPECIFIC DERMAL REGENERATION SHEET AND DIABETIC FOOT PATIENT-SPECIFIC DERMAL REGENERATION SHEET MANUFACTURED USING THE SAME
#9HETERODIMERIC HUMAN IgG1 POLYPEPTIDES WITH ISOELECTRIC POINT MODIFICATIONS
#10HETERODIMERIC HUMAN IgG1 POLYPEPTIDES WITH ISOELECTRIC POINT MODIFICATIONS
#11IMMUNOMODULATORY FUSION PROTEIN-METAL HYDROXIDE COMPLEXES AND METHODS THEREOF
#12COMPOSITIONS AND METHODS FOR ARTIFICIAL PROTOSPACER ADJACENT MOTIF (PAM) GENERATION
#13Programmable Bacteria for the Treatment of Cancer
#14Therapeutic applications based on the inhibition of G Protein-Coupled Receptor 182 (GPR182)
#15Stabilized Nucleic Acids Encoding Messenger Ribonucleic Acid (mRNA)
#16ENGINEERED IMMUNOSTIMULATORY BACTERIAL STRAINS AND USES THEREOF
#17CHIMERIC ANTIGEN RECEPTOR, CELL EXPRESSING SAID RECEPTOR, PHARMACEUTICAL COMPOSITION INCLUDING SAID CELL, METHOD FOR PRODUCING SAID CELL, AND POLYNUCLEOTIDE OR VECTOR INCLUDING NUCLEOTIDE SEQUENCE ENCODING SAID CHIMERIC ANTIGEN RECEPTOR
#18CHIMERIC ANTIGEN RECEPTOR MODIFIED REGULATORY T CELLS FOR TREATING CANCER
#19HETERODIMERIC HUMAN IgG1 POLYPEPTIDES WITH ISOELECTRIC POINT MODIFICATIONS
#20CO-EXPRESSION OF CONSTRUCTS AND IMMUNOSTIMULATORY COMPOUNDS
#21ONCOLYTIC VIRUS COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER
#22RECOMBINANT MVA OR MVADELE3L EXPRESSING HUMAN FLT3L AND USE THEREOF AS IMMUNO-THERAPEUTIC AGENTS AGAINST SOLID TUMORS
#23ALLOGRAFT TOLERANCE WITHOUT THE NEED FOR SYSTEMIC IMMUNE SUPPRESSION
#24MSC-NTF SPECIFIC EXOSOMES AND USE THEREOF
#25Advanced Avatar Dendritic Cells
#26POLYMER MOLECULE, MONOMERIC STRUCTURE AND POLYMERIC STRUCTURE COMPRISING SAME
#27USE OF CXCL14
#28CXCR3 LIGAND HAVING ENHANCED CXCR3-EXPRESSING CELL MIGRATION ACTIVITY
#29Transgenic Immune Cell, Construction Method Therefor and Use Thereof
#30RNA CONSTRUCT
#31ENGINEERED ONCOLYTIC HERPESVIRUSES
#32ADENOVIRUS ARMED WITH BISPECIFIC T CELL ACTIVATOR
#33NOVEL IMMUNE REGULATOR
#34CAR-EXPRESSING IMMUNE CELLS THAT SPECIFICALLY TARGET MESOTHELIN AND USES THEREOF
#35ENGINEERED IMMUNE CELL THAT SPECIFICALLY TARGETS MESOTHELIN AND USES THEREOF
#36Hypoxia-Triggered Artificial Transcription Factor, a Hypoxia-Triggered Transcription Control System and Use Thereof
#37Advanced avatar dendritic cells
#38TCR-T CELL FOR KILLING TUMORS, AND PREPARATION METHOD THEREFOR AND USE THEREOF
#39CX3CR1-BINDING POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS
#40ENHANCER FOR T-CELLS OR B-CELLS HAVING MEMORY FUNCTION, MALIGNANT TUMOR RECURRENCE INHIBITOR, AND INDUCER FOR INDUCING MEMORY FUNCTION IN T-CELLS OR B-CELLS
#41APPLICATION OF GENETICALLY MODIFIED OLIGODENDROCYTE PROGENITOR CELLS IN MULTIPLE SCLEROSIS
#42FULLY HUMAN ANTIBODY FOR HUMAN B7H3, CHIMERIC ANTIGEN RECEPTOR AND USES THEREOF
#43GENETICALLY MODIFIED ONCOLYTIC HERPES SIMPLEX VIRUS DELIVERING CHEMOKINE AND TUMOR ASSOCIATED/SPECIFIC ANTIGEN
#44BISPECIFIC BINDING AGENT-LIGAND FUSIONS FOR THE DEGRADATION OF TARGET PROTEINS
#45ADENOVIRUS ENCODING IL-15
#46Compositions and methods for expression of multiple biologically active polypeptides from a single vector for treatment of cardiac conditions and other pathologies
#47NUCLEIC ACID VECTORS AND METHODS OF USE
#48IMMUNOCOMPETENT CELL THAT EXPRESSES A CELL SURFACE MOLECULE SPECIFICALLY RECOGNIZING HUMAN MESOTHELIN, IL-7 AND CCL19
#49GENETIC ENGINEERING OF MACROPHAGES FOR IMMUNOTHERAPY
#50COMPOSITIONS COMPRISING CHEMERIN AND METHODS OF USE THEREOF
#51CX3CR1-BINDING POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS
#52RECOMBINANT RHABDOVIRUS ENCODING FOR CCL21
#53Allograft tolerance without the need for systemic immune suppression
#54TRANSFORMED IMMUNE CELLS INDUCING CHEMOTAXIS TOWARDS HETEROGENEOUS IMMUNE CELLS
#55Hypoimmunogenic Cells and Methods and Compositions for Their Production
#56Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human Flt3L or GM-CSF for cancer immunotherapy
#57IMMUNOMODULATORY FUSION PROTEIN-METAL HYDROXIDE COMPLEXES AND METHODS THEREOF
#58Stabilized Nucleic Acids Encoding Messenger Ribonucleic Acid (mRNA)
#59A FUSION PROTEON OF STROMAL CELL-DERIVED FACTOR-1 (SDF-1) AND INTERLEUKIN-2 (IL-2) AND APPLICATIONS THEREOF
#60IMMUNOTHERAPY METHOD OF TARGETED CHEMOKINE AND CYTOKINE DELIVERY BY MESENCHYMAL STEM CELL
#61CXCL9 AND VARIANTS THEREOF FOR IMMUNOTHERAPY OF CANCER DISEASES
#62VACCINE COMPOSITIONS COMPRISING C-C MOTIF CHEMOKINE 22 (CCL22) OR FRAGMENTS THEREOF
#63MICROORGANISMS PROGRAMMED TO PRODUCE IMMUNE MODULATORS AND ANTI-CANCER THERAPEUTICS IN TUMOR CELLS
#64MODIFIED CXCL10 FOR IMMUNOTHERAPY OF CANCER DISEASES
#65ANTIMICROBIAL KINOCIDIN COMPOSITIONS AND METHODS OF USE
#66NON-HUMAN ANIMALS HAVING A HUMANIZED CXCL13 GENE
#67Neoepitope immunotherapy with APC targeting unit
#68Fractal Combination Therapy
#69METHODS FOR WOUND HEALING
#70Engineered immunostimulatory bacterial strains and uses thereof
#71ANTI-GPC3 SINGLE-CHAIN ANTIBODY-CONTAINING CAR
#72TAFA4 POLYPEPTIDE OR POLYNUCLEOTIDE FOR TREATING INFLAMMATORY DISEASE
#73Recombinant MVA or MVADELE3L expressing human FLT3L and use thereof as immuno-therapeutic agents against solid tumors
#74ANTIMICROBIAL KINOCIDIN COMPOSITIONS AND METHODS OF USE
#75FUSOKINES INVOLVING CYTOKINES WITH STRONGLY REDUCED RECEPTOR BINDING AFFINITIES
#76Nucleic acids encoding CX3CR1-binding polypeptides comprising immunoglobulin single variable domains
#77VACCINE COMPOSITIONS COMPRISING C-C MOTIF CHEMOKINE 22 (CCL22) OR FRAGMENTS THEREOF
#78Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human Flt3L or GM-CSF for cancer immunotherapy
#79T-CELL MOBILIZING CXCL10 MUTANT WITH INCREASED GLYCOSAMINOGLYCAN BINDING AFFINITY
#80FUSION TOXIN PROTEINS FOR TREATMENT OF DISEASES RELATED TO CMV INFECTIONS
#81VACCINE COMPOSITIONS COMPRISING C-C MOTIF CHEMOKINE 22 (CCL22) OR FRAGMENTS THEREOF
#82Engineered immunostimulatory bacterial strains and uses thereof
#83ANTI-FUGETACTIC AGENT AND ANTI-CANCER AGENT COMBINATION THERAPY AND COMPOSITIONS FOR THE TREATMENT OF CANCER
#84CCL21 AND CHECKPOINT INHIBITORS FOR THE TREATMENT OF CANCER
#85DELIVERY OF MACROMOLECULES INTO THE CENTRAL NERVOUS SYSTEM VIA THE BLOODSTREAM
#86EVASINS FOR USE IN THERAPY AND DIAGNOSTICS
#87COMBINATION IMMUNOTHERAPY
#88Advanced avatar dendritic cells
#89HYDROGEL COMPOSITIONS AND METHODS FOR TREATEMENT OF MALIGNANCIES
#90COMPOSITIONS AND METHODS FOR EXPRESSION OF MULTIPLE BIOLOGICALLY ACTIVE POLYPEPTIDES FROM A SINGLE VECTOR FOR TREATMENT OF CARDIAC CONDITIONS AND OTHER PATHOLOGIES
#91MAXIMIZING T-CELL MEMORY AND COMPOSITIONS AND METHODS THEREFOR
#92METHODS AND COMPOSITONS FOR MODULATIONS OF IMMUNE RESPONSE
#93CXCR3 LIGAND
#94IMMUNOMODULATORY CELLS AND USES THEREOF
#95PROTEASE RESISTANT MUTANTS OF STROMAL CELL DERIVED FACTOR-1 IN THE REPAIR OF TISSUE DAMAGE
#96METHOD OF MANUFACTURING DIABETIC FOOT PATIENT-SPECIFIC DERMAL REGENERATION SHEET AND DIABETIC FOOT PATIENT-SPECIFIC DERMAL REGENERATION SHEET MANUFACTURED USING THE SAME
#97CHIMERIC ANTIGEN RECEPTORS (CARs) COMPOSITIONS AND METHODS OF USE THEREOF
#98CHEMOKINE RESPONSIVE ACTIVATED NATURAL KILLER CELLS WITH SECONDARY HOMING ACTIVATION FOR VERIFIED TARGETS
#99PROGRAMMABLE BACTERIA FOR THE TREATMENT OF CANCER
#100HETERODIMERIC HUMAN IgG1 POLYPEPTIDES WITH ISOELECTRIC POINT MODIFICATIONS
#101CAR EXPRESSION VECTOR AND CAR-EXPRESSING T CELLS
#102PROTEASE RESISTANT MUTANTS OF STROMAL CELL DERIVED FACTOR-1 IN THE REPAIR OF TISSUE DAMAGE
#103GENETICALLY ENGINEERED CELL AND APPLICATION THEREOF
#104ANTIMICROBIAL KINOCIDIN COMPOSITIONS AND METHODS OF USE
#105Targeted Critical Fluid Nanoparticles Platform for Delivery of Nucleic Acids for Treatment of HIV-1 and Other Diseases
#106ALLOGRAFT TOLERANCE WITHOUT THE NEED FOR SYSTEMIC IMMUNE SUPPRESSION
#107RECOMBINANT ADENO-ASSOCIATED VIRUS-MEDIATED EXPRESSION OF FRACTALKINE FOR TREATMENT OF NEUROINFLAMMATORY AND NEURODEGENERATIVE DISEASES
#108ENGINEERED IMMUNOSTIMULATORY BACTERIAL STRAINS AND USES THEREOF
#109MSC-NTF specific exosomes and use thereof
#110Immunoglobulin complex comprising interleukin-15
#111Antitumor peptide and use thereof
#112Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof
#113Vault complexes for cytokine delivery
#114Methods of treating inflammation with monomeric CXCL12 peptide
#115IMMUNOCOMPETENT CELL THAT EXPRESSES A CELL SURFACE MOLECULE SPECIFICALLY RECOGNIZING HUMAN MESOTHELIN, IL-7 AND CCL19
#116USE OF CXCL12 TO PROMOTE SURVIVAL, FUNCTION, AND IMMUNOISOLATION OF STEM CELL-DERIVED BETA CELLS
#117Recombinant MVA or MVAΔE3L expressing human FLT3L and use thereof as immuno-therapeutic agents against solid tumors
#118Methods for wound healing
#119NANOSTRUCTURED PROTEINS AND USES THEREOF
#120Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human FLT3L or GM-CSF for cancer immunotherapy
#121Recombinant rhabdovirus encoding for CCL21
#122Engineered immunostimulatory bacterial strains and uses thereof
#123Stabilized nucleic acids encoding messenger ribonucleic acid (mRNA)
#124Genetic engineering of macrophages for immunotherapy
#125NK cell-activating fusion protein, NK cell, and pharmaceutical composition including same
#126Anti-fugetactic agent and anti-cancer agent combination therapy and compositions for the treatment of cancer
#127ANTIMICROBIAL KINOCIDIN COMPOSITIONS AND METHODS OF USE
#128Maximizing T-cell memory and compositions and methods therefor
#129Methods and compositions using recombinant dendritic cells for cancer therapy
#130Peptide inhibition of CCR3-mediated diseases or conditions
#131Fractal combination therapy
#132Biomarkers for anti-IL4-IL13 bispecific antibodies
#133Phage conjugates and uses thereof
#134Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells
#135CAR expression vector and CAR-expressing T cells
#136Compositions and methods comprising permuted protein tags for facilitating overexpression, solubility, and purification of target proteins
#137CHEMOKINE-CYTOKINE FUSION PROTEINS AND THEIR APPLICATIONS
#138High affinity CXCR4 selective binding conjugate and method for using the same
#139Adenovirus armed with bispecific T cell engager
#140Oncolytic group B adenovirus expressing a stroma-targeted bispecific t-cell engager
#141Immunomodulatory polypeptides and related compositions and methods
#142Composition for improving skin condition comprising chemokines
#143Antimicrobial kinocidin compositions and methods of use
#144NK cells with altered CXCL12/CXCR4 signaling
#145EVASINS FOR USE IN THERAPY AND DIAGNOSTICS
#146CHEMOKINE-IMMUNOGLOBULIN FUSION POLYPEPTIDES, COMPOSITIONS, METHOD OF MAKING AND USE THEREOF
#147Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human Flt3L or GM-CSF for cancer immunotherapy
#148Recombinant MVA or MVADELE3L expressing human FLT3L and use thereof as immuno-therapeutic agents against solid tumors
#149Fusokines involving cytokines with strongly reduced receptor binding affinities
#150Compositions comprising chemerin and methods of use thereof
#151Vaccine compositions comprising C—C motif chemokine 22 (CCL22) or fragments thereof
#152Glycosaminoglycan-antagonising fusion proteins
#153Compositions and methods for expression of multiple biologically active polypeptides from a single vector for treatment of cardiac conditions and other pathologies
#154SECRETORY TNT CAR CELL IMMUNOTHERAPY
#155Engineered CCL20 locked dimer polypeptide
#156MODIFIED CXCL12 POLYPEPTIDES AND USES THEREOF
#157Combination immunotherapy
#158Methods for wound healing
#159Fusokines involving cytokines with strongly reduced receptor binding affinities
#160Monomeric CXCL121 peptide and methods of treating autoimmune diseases
#161Laser-assisted intradermal administration of active substances
#162ANTI-FUGETACTIC AGENT AND ANTI-CANCER AGENT COMBINATION THERAPY AND COMPOSITIONS FOR THE TREATMENT OF CANCER
#163Class of therapeutic protein based molecules
#164Chemokine-cytokine fusion proteins of SDF-1 and CD40L
#165Peptide inhibition of CCR3-mediated diseases or conditions
#166Car expression vector and car-expressing T cells
#167Pegylated recombinant bacteriophage
#168ANTI-IL4-IL 13 BISPECIFIC ANTIBODIES
#169Vault complexes for cytokine delivery
#170ANTIMICROBIAL KINOCIDIN COMPOSITIONS AND METHODS OF USE
#171Methods and compositions for modulating immune tolerance
#172Protease resistant mutants of stromal cell derived factor-1 in the repair of tissue damage
#173Genetic engineering of macrophages for immunotherapy
#174Glycosaminoglycan-antagonising fusion proteins and methods of using same
#175Novel Brain Chemokine Samdori and Use Thereof
#176Chemokine-immunoglobulin fusion polypeptides, compositions, method of making and use thereof
#177Engineered cytokine- and chemokine-expressing strains and methods of use
#178SDF-1 binding nucleic acids and the use thereof
#179Peptide for promoting osteogenic differentiation or vascularization and use thereof
#180Use of CCL1 in therapy
#181Class of therapeutic protein based molecules
#182Chemokine-immunoglobulin fusion polypeptides, compositions, method of making and use thereof
#183MRG RECEPTOR MODULATORS
#184NOVEL POLYPEPTIDES
#185ANTI-CXCL13 ANTIBODIES AND ASSOCIATED EPITOPE SEQUENCES
#186Monomeric CXCL12peptide and methods of use thereof
#187Albumin fusion proteins
#188NON-VIRAL VECTOR
#189CHEMOKINE-CYTOKINE FUSION PROTEINS AND THEIR APPLICATIONS
#190Microtubule-modifying compound
#191Albumin fusion proteins
#192Chemokine-immunoglobulin fusion polypeptides, compositions, method of making and use thereof
#193Vault complexes for cytokine delivery
#194Polypeptide structural motifs associated with cell signaling activity
#195SDF-1 Binding Nucleic Acids and the Use Thereof
#196Methods and compositions for modulating immune tolerance
#197Class of therapeutic protein based molecules
#198Recombinant adeno-associated virus-mediated expression of fractalkine for treatment of neuroinflammatory and neurodegenerative diseases
#199SDF-1 delivery for treating ischemic tissue
#200HIGH LEVEL PRODUCTION OF RECOMBINANT PROTEINS
#201Protease resistant mutants of stromal cell derived factor-1 in the repair of tissue damage
#202Control agent for controlling undifferentiated state and use thereof
#203Class of therapeutic protein based molecules
#204Engineered CXCL12 alpha locked dimer polypeptide
#205Chemokine-immunoglobulin fusion polypeptides, compositions, method of making and use thereof
#206SDF-1 delivery for treating ischemic tissue
#207VIRAL CHEMOKINE-ANTIGEN FUSION PROTEINS
#208Heterodimeric human IgG1 polypeptides with isoelectric point modifications
#209Antagonists for diseases induced by cells with high-affinity ELR-CXC chemokine receptor proteins
#210Methods and compositions containing Fc fusion proteins for enhancing immune responses
#211COMPOSITIONS AND METHODS FOR USING AND IDENTIFYING ANTIMICROBIAL AGENTS
#212Chemokine-immunoglobulin fusion polypeptides, compositions, method of making and use thereof
#213SDF-1 delivery for treating ischemic tissue
#214SDF-1 delivery for treating ischemic tissue
#215SDF-1 DELIVERY FOR TREATING ISCHEMIC TISSUE
#216Viral chemokine-antigen fusion proteins
#217Human aminoacyl-tRNA synthetase polypeptides useful for the regulation of angiogenesis
#218Creating bioengineered lymph nodes
#219Tryptophanyl-tRNA synthetase-derived polypeptides useful for the regulation of angiogenesis
#220Method for blocking binding of CX3C chemokines using CX3C chemokine antibodies
#221Vault complexes for cytokine delivery
#222Signature Of Secreted Protein Isoforms Specific To Ovarian Cancer
#223Proteins
#224CCL17
#225Chemokine-Chaperone Fusion Proteins
#226Albumin fusion proteins
#227POLYPEPTIDE STRUCTURAL MOTIFS ASSOCIATED WITH CELL SIGNALING ACTIVITY
#228Antimicrobial kinocidin compositions and methods of use
#229PROTEASE RESISTANT MUTANTS OF STROMAL CELL DERIVED FACTOR-1 IN THE REPAIR OF TISSUE DAMAGE
#230Chemokine containing apheresis column and methods of use
#231TARGETED COSTIMULATORY POLYPEPTIDES AND METHODS OF USE TO TREAT CANCER
#232SDF-1 binding nucleic acids and the use thereof
#233PD-1 ANTAGONISTS AND METHODS OF USE THEREOF
#234Mouse CX3C chemokine polypeptides
#235Class of therapeutic protein based molecules
#236Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders
#237PD-1 ANTAGONISTS AND METHODS FOR TREATING INFECTIOUS DISEASE
#238ANTIMICROBIAL POLYPEPTIDE
#239Antimicrobial kinocidin compositions and methods of use
#240GM-CSF and truncated CCL2 conjugates and methods and uses thereof
#241Viral chemokine-antigen fusion proteins
#242Human aminoacyl-tRNA synthetase polypeptides useful for the regulation of angiogenesis
#243Engineered CXCL12 alpha locked dimer polypeptide
#244Methods and compositions for modulating immune tolerance
#245CHEMOKINE ANALOGS
#246Albumin fusion proteins
#247IMMUNOGLOBULIN FUSION PROTEINS
#248Protease resistant mutants of stromal cell derived factor-1 in the repair of tissue damage
#249ANTIMICROBIAL KINOCIDIN COMPOSITIONS AND METHODS OF USE
#250TNF-alpha VACCINE FOR TREATING DISEASE CONDITIONS MEDIATED BY PATHOLOGICAL TNF-alpha
#251MAMMALIAN CHEMOKINES; RECEPTORS; REAGENTS; USES
#252Immunotoxins for the treatment of diseases related to CMV infection
#253hG31P Expression System
#254Mammalian CXC chemokine antibodies
#255Engineered CXCL12 α locked dimer polypeptide
#256Tryptophanyl-tRNA synthetase-derived polypeptides useful for the regulation of angiogenesis
#257Human aminoacyl-tRNA synthetase polypeptides useful for the regulation of angiogenesis
#258Engineered fusion molecules immunotherapy in cancer and inflammatory diseases
#259PEPTIDES AND COMPOUNDS THAT BIND TO A RECEPTOR
#260Recombinant chemokine-antigen vaccine
#261Non-natural chemokine receptor ligands and methods of use thereof
#262RNAi-MEDIATED INHIBITION OF STROMAL CELL-DERIVED FACTOR 1-RELATED TARGETS FOR TREATMENT OF NEOVASCULARIZATION-RELATED CONDITIONS
#263Albumin Fusion Proteins
#264Albumin Fusion Proteins
#265Molecule associating with intracellular C-terminal domain of receptor
#266Methods for construction and screening of libraries of chemokine variants
#267Leukocyte Adhesion Inhibitor-1 (LAI-1)
#268Mammalian CXC chemokine antibodies
#269Antibodies to Chemokine Alpha-5
#270CC-chemokine binding tick proteins
#271Myeloid progenitor inhibitory factor-1 (MPIF-1) polypeptides
#272Albumin fusion proteins
#273IL-8 Like Protein
#274Albumin Fusion Proteins
#275Albumin fusion proteins comprising insulin polypeptides
#276Albumin Fusion Proteins
#277G-CSF-albumin fusion proteins
#278Albumin fusion proteins
#279MAMMALIAN CHEMOKINES; RECEPTORS; REAGENTS; USES
#280Protease resistant mutants of stromal cell derived factor-1 in the repair of tissue damage
#281Tryptophanyl-tRNA synthetase-derived polypeptides useful for the regulation of angiogenesis
#282Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity
#283Polypeptide fragments of CKLF1
#284Novel chemokine mimetics synthesis and their use
#285Albumin fusion proteins
#286Albumin fusion proteins
#287Tryptophanyl-tRNA synthetase-derived polypeptides useful for the regulation of angiogenesis
#288Synthetic chemokine receptor ligands and methods of use thereof
#289Composition and method for inducing protective vaccine response
#290Peptides and compounds that bind to a receptor
#291Methods and materials relating to novel polypeptides and polynucleotides
#292Compositions and methods for cancer immunotherapy
#293Effectors of innate immunity
#294Purposeful movement of human migratory cells away from an agent source
#295Mono-and bi-functional antibody conjugates as effective adjuvants of protein vaccination
#296Albumin fusion proteins
#297Methods of treating inflammation using mammalian CXC chemokine antibodies
#298DNAXCCR10
#299Chemokine mimetics synthesis and their use
#300Method of peptide synthesis of peptides containing a proline residue or hydroxyproline residue at or adjacent to the C-terminal end of the peptide